Photobiomodulation Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorJessa Hospital
About this trial
This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the management of chemotherapy-induced peripheral neuropathy (CIPN). Therefore, the hypothesis is that PBM can reduce the severity of CIPN in cancer patients, increasing the patient's quality of life.
Eligibility criteria
Qualifiers
Finished one of the following types of chemotherapy: paclitaxel, docetaxel, oxaliplatin, cisplatin, vincristine, thalidomide and/or bortezomib.
Diagnosed with CIPN
Age 18 years or above
Have no documented or observable psychiatric or neurological disorders that might interfere with study participation (e.g., dementia or psychosis)
Disqualifiers
Taking stable doses of medication on prescription for peripheral neuropathy. Related medications are: gabapentin, pregabalin (Lyrica), nortriptyline, amitriptyline, duloxetine (Cymbalta), and venlafaxine.
Severe or unstable cardio- respiratory or musculoskeletal disease
Interruption of more than two consecutive laser treatments
Dark brown or black skin pigmentation (described as skin type VI in the Fitzpatrick scale)
Trial design
Treatments tested in this trial
- Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)
Treatment groups
172 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov